Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Pro Medicus Limited ( (AU:PME) ) just unveiled an update.
Pro Medicus Limited’s U.S. subsidiary, Visage Imaging, Inc., has secured a significant 5-year, A$44M contract with Advanced Radiology Management, a prominent private radiology group. This agreement involves implementing the cloud-based Visage 7 Enterprise Imaging Platform, which aims to enhance diagnostic interpretation efficiency. The rollout is set to begin immediately, with the platform expected to go live by late Q2 2026. This contract underscores Pro Medicus’s growing influence in the North American healthcare IT market and addresses the increasing demand for efficient radiology solutions amid a global shortage of radiologists.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$290.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
More about Pro Medicus Limited
Pro Medicus Limited is a leading healthcare informatics company founded in 1983. It provides a comprehensive range of medical imaging software and services to hospitals, imaging centers, and healthcare groups worldwide. The company is known for its Visage 7 suite of products, which offer ultra-fast, clinically rich, and highly scalable imaging solutions deployable in both public and private cloud environments. Pro Medicus has offices in Melbourne, Berlin, and San Diego.
YTD Price Performance: -0.32%
Average Trading Volume: 173,502
Technical Sentiment Signal: Buy
Current Market Cap: A$26.01B
Learn more about PME stock on TipRanks’ Stock Analysis page.